MedTrace Logo

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

NCT00297947 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-04-17

No results posted yet for this study

Summary

This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of quetiapine.

Conditions

Interventions

DRUG

quetiapine

Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.

DRUG

quetiapine

Participant will receive 600 mg/day of quetiapine for 8 weeks.

Sponsors & Collaborators

  • Nathan Kline Institute for Psychiatric Research

    collaborator OTHER

  • Manhattan Psychiatric Center

    lead OTHER

Principal Investigators

  • Jean-Pierre Lindenmayer, MD · Manhattan Psychiatric Center

  • Leslie Citrome, MD · Nathan Kline Institute for Psychiatric Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297947 on ClinicalTrials.gov